Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: A CRUCIAL trial subanalysis

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 145-156

  Cho, Eun Joo ^a   Kim, Jae Hyung ^a   Sutradhar, Santosh ^b   Yunis, Carla ^b   Westergaard, Mogens ^b  

^a The Catholic University of Korea   (South Korea)

^b PFIZER INC   (United States)

Author keywords

Anticholesteremic agents; Antihypertensive agents; Cardiovascular disease; Clinical trial; Hypertension; Risk factors

Indexed keywords

CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROATIA; CZECH REPUBLIC; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN TISSUE; INDONESIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MEXICO; PACIFIC ISLANDS; PHILIPPINES; POPULATION RISK; RISK REDUCTION; RUSSIAN FEDERATION; SOUTH KOREA; TAIWAN; THAILAND;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HYPERTENSION; RISK FACTORS;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ASIA; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG COMBINATIONS; DYSLIPIDEMIAS; EUROPE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LATIN AMERICA; MALE; MIDDLE AGED; MIDDLE EAST; PREVENTIVE HEALTH SERVICES; PROSPECTIVE STUDIES; PYRROLES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897980007     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S54586     Document Type: Article

References (32)

1. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157-2172.
2. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31(12):2115-2127.
3. Muramatsu T, Matsushita K, Yamashita K, etal; NAGOYA HEART Study Investigators. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension. 2012;59(3):580-586.
4. Yusuf S, Hawken S, Ounpuu S, etal; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
5. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104(23):2855-2864.
6. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177-1181.
7. Yagi H, Komukai K, Hashimoto K, etal. Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol. 2010;55(3):345-353.
8. Lawes CM, Rodgers A, Bennett DA, etal; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707-716.
9. Gupta AK, Poulter NR, Dobson J, etal; ASCOT investigators. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens. 2010;23(9):1023-1030.
10. Zamorano J, Erdine S, Pavia A, etal; CRUCIAL Investigators. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011;27(4):821-833.
11. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
12. Erdine S, Ro YM, Tse HF, etal; Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens. 2009;23(3):196-210.
13. Richard Hobbs FD, Gensini G, John Mancini GB, etal; JEWEL Study Group. International open-label program to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009;16(4):472-480.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
15. Sever PS, Dahlöf B, Poulter NR, etal; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
16. Hussein MA, Chapman RH, Benner JS, etal. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs. 2010;10(3):193-202.
17. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med J Aust. 2011;195(3):134-137.
18. Zamorano J, Erdine S, Lopez AP, etal; CRUCIAL Investigators. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med. 2010;122(2):7-15.
19. Chobanian AV, Bakris GL, Black HR, etal. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
21. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12 Pt 1):1823-1829.
22. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99: 410-414.
23. Nakamura H, Arakawa K, Itakura H, etal; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163.
24. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101(3A):22S-32S.
25. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol. 1994;73(3):2A-9A
26. Masaki Y, Shimada K, Kojima T, etal. Clinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantation. J Cardiol. 2011;57(3):303-310.
27. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431.
28. Radha V, Vimaleswaran KS, Babu HN, etal. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diabetes Care. 2006;29(5): 1046-1051.
29. Chan JC, Malik V, Jia W, etal. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129-2140.
30. Kenealy T, Elley CR, Robinson E, etal. An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand. Diabet Med. 2008;25(11):1302-1308.
31. Menotti A, Lanti M, Kromhout D, etal. Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study. Eur J Cardiovasc Prev Rehabil. 2008;15(6):719-725.
32. Cho EJ, Kim JH, Sutradhar S, Yunis C, Westergaad M; CRUCIAL Trial Investigators. Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific-Asian patients participating in the CRUCIAL trial. J Korean Med Sci. 2013;28(12):1741-1748.